Quantcast

Latest zolpidem Stories

2011-01-31 07:02:00

POINT RICHMOND, Calif., Jan. 31, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that the U.S. Food and Drug Administration (FDA) has classified the recent Intermezzo® New Drug Application (NDA) resubmission as a complete Class 2 response and assigned a Prescription Drug User Fee Act (PDUFA) action date of July 14, 2011 for the completion of the NDA review. (Logo: http://photos.prnewswire.com/prnh/20101102/SF93452LOGO) About...

2011-01-13 14:55:04

Adults who take one of the world's most commonly prescribed sleep medications are significantly more at risk for nighttime falls and potential injury, according to a new study by the University of Colorado at Boulder. The study, which involved 25 healthy adults, showed 58 percent of the older adults and 27 percent of the young adults who took a hypnotic, sleep-inducing drug called zolpidem showed a significant loss of balance when awakened two hours after sleep. The findings are important...

2010-11-08 14:54:26

When sleep doesn't come easily, some people turn to what they think is an easy solution "“ sleeping pills. But according to a Baylor College of Medicine sleep expert, sleep medications "“ whether prescription or over-the-counter "“ shouldn't be taken lightly. "All medications have side effects that need to be weighed whenever you take them," cautioned Dr. Phil Alapat, assistant professor of pulmonary, critical care and sleep medicine at BCM and medical director of the BCM...

2010-10-18 23:19:00

POINT RICHMOND, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced its preliminary analysis of data from the recently completed Intermezzo® 3.5 mg (zolpidem tartrate sublingual tablet) highway driving study. Transcept is developing Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. In the...

2010-10-18 17:00:00

MORRISTOWN, N.J., Oct. 18 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV. Distribution of the product has commenced. As the first company to file an ANDA that contained a paragraph IV certification for Ambien® CR 6.25mg, Actavis has been awarded 180-day exclusivity to market this...

2010-09-29 15:05:00

POINT RICHMOND, Calif., Sept. 29 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present a general business overview at the BIO Investor Forum in San Francisco on October 6, 2010 at 3:00 p.m. PDT. A live audio webcast and replay of this...

2010-09-20 04:29:00

DALLAS, September 20, 2010 /PRNewswire/ -- ReportsandReports announces it will carry Insomnia Market Forecast Research Report in its store. Browse the complete Report on: http://www.reportsandreports.com/reports/33201-insomnia-market-forecast.html Search More Then 50000 Market Research Reports at ReportsandReports (http://www.reportsandreports.com/) Browse All Datamonitor Research Reports at http://www.reportsandreports.com/Publishers/datamonitor/ The availability of...

2010-03-23 15:03:00

POINT RICHMOND, Calif., March 23 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that the second patent covering the composition and use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office. Transcept has previously announced the issuance of a Notice of Allowance for claims under the application for this patent, U.S. Patent...

2010-02-22 15:35:00

POINT RICHMOND, Calif., Feb. 22 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced today an update on its plans to seek U.S. Food and Drug Administration (FDA) approval of Intermezzo® (zolpidem tartrate sublingual tablet) for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Transcept met with the FDA on January 20, 2010 to discuss the Complete Response Letter...

230055f97bcfdfb0067ea16615d2d9881
2010-02-11 06:50:00

Scientists announced Wednesday they have solved the mystery behind why people become addicted to a class of prescription drugs that includes some anti-depressants, muscle relaxants and sleeping pills, reported AFP. Reported in the British science journal Nature, researchers hope the findings will pave the way for the development of new treatments that can alleviate symptoms without resulting in addiction. Scientists know that drugs like opium, heroin and cannabinoids are addictive because...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related